chlorthalidone has been researched along with Essential Hypertension in 12 studies
Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.
Essential Hypertension: Hypertension that occurs without known cause, or preexisting renal disease. Associated polymorphisms for a number of genes have been identified, including AGT, GNB3, and ECE1. OMIM: 145500
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the study was to evaluate the efficacy and safety of fixed-dose combination (FDC) of metoprolol, telmisartan, and chlorthalidone in patients with essential hypertension and stable coronary artery disease (CAD) who showed inadequate response to dual therapy." | 9.51 | Fixed-dose Combination of Metoprolol, Telmisartan, and Chlorthalidone for Essential Hypertension in Adults with Stable Coronary Artery Disease: Phase III Study. ( Agrawal, S; Anand, J; Bachani, D; Doshi, M; Gaikwad, VB; Halder, SK; Kinholkar, B; Kumar, DA; Kumbhar, A; Mathur, R; Mehta, S; Sarkar, G; Sharma, A, 2022) |
| " There are no serious adverse event and no one discontinued medication due to adverse event." | 7.30 | Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double-blind, active-controlled, multicenter phase 3 trial. ( Ahn, Y; Cha, KS; Chang, K; Cho, EJ; Choi, DJ; Choi, SY; Doh, JH; Hong, SJ; Hong, SP; Hwang, JY; Hyon, MS; Ihm, SH; Kang, WC; Kim, HS; Kim, MH; Kim, SH; Kim, WS; Kim, YH; Kwon, K; Lee, JH; Lee, N; Lim, SW; Rhee, MY; Shin, J; Son, JW; Yoo, BS, 2023) |
| "The aim of the study was to evaluate the efficacy and safety of fixed-dose combination (FDC) of metoprolol, telmisartan, and chlorthalidone in patients with essential hypertension and stable coronary artery disease (CAD) who showed inadequate response to dual therapy." | 5.51 | Fixed-dose Combination of Metoprolol, Telmisartan, and Chlorthalidone for Essential Hypertension in Adults with Stable Coronary Artery Disease: Phase III Study. ( Agrawal, S; Anand, J; Bachani, D; Doshi, M; Gaikwad, VB; Halder, SK; Kinholkar, B; Kumar, DA; Kumbhar, A; Mathur, R; Mehta, S; Sarkar, G; Sharma, A, 2022) |
| "The aim of this clinical trial was to assess the efficacy and safety of low-dose triple combinations of amlodipine, telmisartan, and chlorthalidone in patients with essential hypertension." | 5.51 | Efficacy and safety of low-dose antihypertensive combination of amlodipine, telmisartan, and chlorthalidone: A randomized, double-blind, parallel, phase II trial. ( Ahn, JC; Cho, EJ; Han, SH; Kang, SM; Kim, KH; Kim, KI; Kim, SY; Kim, W; Kim, YJ; Park, CG; Park, SJ; Park, SM; Shin, J; Shin, JH; Sohn, IS; Sung, JH; Sung, KC, 2022) |
| "This 52-week, randomized, open-label study evaluated long-term safety/tolerability of fixed-dose combination azilsartan medoxomil/chlorthalidone (AZL-M/CLD) vs fixed-dose combination olmesartan medoxomil/hydrochlorothiazide (OLM/HCTZ) in patients with essential hypertension (stage 2; clinic systolic blood pressure 160-190 mm Hg)." | 5.24 | Comparison of long-term safety of fixed-dose combinations azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide. ( Barger, B; Cushman, WC; Handley, A; Lloyd, E; Neutel, JM, 2017) |
| " There are no serious adverse event and no one discontinued medication due to adverse event." | 3.30 | Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double-blind, active-controlled, multicenter phase 3 trial. ( Ahn, Y; Cha, KS; Chang, K; Cho, EJ; Choi, DJ; Choi, SY; Doh, JH; Hong, SJ; Hong, SP; Hwang, JY; Hyon, MS; Ihm, SH; Kang, WC; Kim, HS; Kim, MH; Kim, SH; Kim, WS; Kim, YH; Kwon, K; Lee, JH; Lee, N; Lim, SW; Rhee, MY; Shin, J; Son, JW; Yoo, BS, 2023) |
| " Adverse events (AEs) were reported in 75." | 2.82 | Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study. ( Barger, B; Handley, A; Lloyd, E; Roberts, A, 2016) |
| "Hypertension is a modifiable cardiovascular risk factor." | 2.50 | Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. ( Bassett, K; Musini, VM; Nazer, M; Wright, JM, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sarkar, G | 1 |
| Gaikwad, VB | 1 |
| Sharma, A | 1 |
| Halder, SK | 1 |
| Kumar, DA | 1 |
| Anand, J | 1 |
| Agrawal, S | 1 |
| Kumbhar, A | 1 |
| Kinholkar, B | 1 |
| Mathur, R | 1 |
| Doshi, M | 1 |
| Bachani, D | 1 |
| Mehta, S | 1 |
| Sung, KC | 1 |
| Sung, JH | 1 |
| Cho, EJ | 2 |
| Ahn, JC | 1 |
| Han, SH | 1 |
| Kim, W | 1 |
| Kim, KH | 1 |
| Sohn, IS | 1 |
| Shin, J | 2 |
| Kim, SY | 1 |
| Kim, KI | 1 |
| Kang, SM | 1 |
| Park, SJ | 1 |
| Kim, YJ | 1 |
| Shin, JH | 1 |
| Park, SM | 1 |
| Park, CG | 1 |
| Kim, MH | 1 |
| Kim, YH | 1 |
| Chang, K | 1 |
| Choi, DJ | 1 |
| Kang, WC | 1 |
| Kim, SH | 1 |
| Lee, N | 1 |
| Son, JW | 1 |
| Doh, JH | 1 |
| Kim, WS | 1 |
| Hong, SJ | 1 |
| Rhee, MY | 1 |
| Ahn, Y | 1 |
| Lim, SW | 1 |
| Hong, SP | 1 |
| Choi, SY | 1 |
| Hyon, MS | 1 |
| Hwang, JY | 1 |
| Kwon, K | 1 |
| Cha, KS | 1 |
| Ihm, SH | 1 |
| Lee, JH | 1 |
| Yoo, BS | 1 |
| Kim, HS | 1 |
| Neutel, JM | 1 |
| Cushman, WC | 1 |
| Lloyd, E | 3 |
| Barger, B | 2 |
| Handley, A | 2 |
| Singh, S | 1 |
| McDonough, CW | 2 |
| Gong, Y | 2 |
| Alghamdi, WA | 1 |
| Arwood, MJ | 1 |
| Bargal, SA | 1 |
| Dumeny, L | 1 |
| Li, WY | 1 |
| Mehanna, M | 2 |
| Stockard, B | 1 |
| Yang, G | 1 |
| de Oliveira, FA | 1 |
| Fredette, NC | 1 |
| Shahin, MH | 1 |
| Bailey, KR | 2 |
| Beitelshees, AL | 2 |
| Boerwinkle, E | 1 |
| Chapman, AB | 2 |
| Gums, JG | 2 |
| Turner, ST | 2 |
| Cooper-DeHoff, RM | 2 |
| Johnson, JA | 2 |
| Collier, DJ | 1 |
| Juhasz, A | 1 |
| Agabiti-Rosei, E | 1 |
| Hisada, M | 1 |
| Zhao, L | 1 |
| Kupfer, S | 1 |
| Caulfield, MJ | 1 |
| Wang, Z | 1 |
| Schwartz, GL | 1 |
| Musini, VM | 1 |
| Nazer, M | 1 |
| Bassett, K | 1 |
| Wright, JM | 1 |
| Roberts, A | 1 |
| BERGSTROEM, J | 1 |
| ARNOLD, OH | 1 |
| MIZGALA, HF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Parallel, Multi-Center, Phase 2 Clinical Trial to Determine the Optimal Dose of AD-209 in Patients With Essential Hypertension[NCT04218552] | Phase 2 | 176 participants (Actual) | Interventional | 2020-02-25 | Completed | ||
| Pharmacogenomic Evaluation of Antihypertensive Responses 2[NCT01203852] | Phase 4 | 839 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)[NCT00246519] | Phase 4 | 1,701 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Genetic Epidemiology of Responses to Antihypertensives[NCT00005520] | 1,200 participants (Actual) | Observational | 1997-02-28 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in glucose after treatment with study medication (NCT01203852)
Timeframe: after 6-8 weeks treatment
| Intervention | mg/dL (Mean) | |
|---|---|---|
| glucose response to metoprolol (n=365) | glucose response to chlorthalidone (n=318) | |
| Adverse Metabolic Effects | 1.02 | 5.12 |
Response to blood pressure medication will be assessed by measuring blood pressure before and after treatment (NCT01203852)
Timeframe: after 6-8 weeks of treatment
| Intervention | mmHg (Mean) | |
|---|---|---|
| diastolic blood pressure response | systolic blood pressure response | |
| Chlorthalidone Only | -7.68 | -13.65 |
| Metoprolol + Chlorthalidone | -7.56 | -11.70 |
| Metorprolol Only | -7.97 | -7.45 |
(NCT00246519)
Timeframe: baseline to 18 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Atenolol +HCTZ Arm | -12.06 |
| HCTZ + Atenolol | -13.33 |
3 reviews available for chlorthalidone and Essential Hypertension
| Article | Year |
|---|---|
Genome Wide Association Study Identifies the
Topics: Adult; Antihypertensive Agents; Biomarkers; Black or African American; Blood Glucose; Blood Pressure | 2018 |
Genome Wide Association Study Identifies the
Topics: Adult; Antihypertensive Agents; Biomarkers; Black or African American; Blood Glucose; Blood Pressure | 2018 |
Genome Wide Association Study Identifies the
Topics: Adult; Antihypertensive Agents; Biomarkers; Black or African American; Blood Glucose; Blood Pressure | 2018 |
Genome Wide Association Study Identifies the
Topics: Adult; Antihypertensive Agents; Biomarkers; Black or African American; Blood Glucose; Blood Pressure | 2018 |
Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Essential Hypertension; Humans; Hydr | 2014 |
NEWER DRUGS IN THE TREATMENT OF HYPERTENSION.
Topics: Antihypertensive Agents; Bretylium Compounds; Chlorothiazide; Chlorthalidone; Diuretics; Drug Therap | 1965 |
6 trials available for chlorthalidone and Essential Hypertension
| Article | Year |
|---|---|
Fixed-dose Combination of Metoprolol, Telmisartan, and Chlorthalidone for Essential Hypertension in Adults with Stable Coronary Artery Disease: Phase III Study.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Coronary Artery Disease; | 2022 |
Efficacy and safety of low-dose antihypertensive combination of amlodipine, telmisartan, and chlorthalidone: A randomized, double-blind, parallel, phase II trial.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Double-Blind Method; Drug Combi | 2022 |
Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double-blind, active-controlled, multicenter phase 3 trial.
Topics: Aged; Amlodipine; Chlorthalidone; Essential Hypertension; Female; Humans; Hypertension; Leukemia, My | 2023 |
Comparison of long-term safety of fixed-dose combinations azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2017 |
Efficacy and safety of azilsartan medoxomil/chlortalidone fixed-dose combination in hypertensive patients uncontrolled on azilsartan medoxomil alone: A randomized trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Blood Pressure; Blood Pressure Monito | 2018 |
Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study.
Topics: Adult; Aged; Benzimidazoles; Chlorthalidone; Cohort Studies; Dizziness; Drug Therapy, Combination; E | 2016 |
3 other studies available for chlorthalidone and Essential Hypertension
| Article | Year |
|---|---|
Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Biomarkers; Black or African American; Blood Press | 2019 |
Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Biomarkers; Black or African American; Blood Press | 2019 |
Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Biomarkers; Black or African American; Blood Press | 2019 |
Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Biomarkers; Black or African American; Blood Press | 2019 |
Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Biomarkers; Black or African American; Blood Press | 2019 |
Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Biomarkers; Black or African American; Blood Press | 2019 |
Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Biomarkers; Black or African American; Blood Press | 2019 |
Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Biomarkers; Black or African American; Blood Press | 2019 |
Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Biomarkers; Black or African American; Blood Press | 2019 |
[EFFECT OF HYGROTON ON CELL ELECTROLYTES IN PATIENTS WITH ESSENTIAL HYPERTENSION].
Topics: Biopsy; Blood Chemical Analysis; Blood Pressure Determination; Chlorides; Chlorthalidone; Electrolyt | 1964 |
[THERAPY OF ESSENTIAL HYPERTENSION].
Topics: Benzothiadiazines; Chlorthalidone; Diuretics; Drug Therapy; Essential Hypertension; Guanethidine; Hu | 1965 |